SynthesisActa oncologica (Stockholm, Sweden)2025
Coasting related to taxane-induced peripheral neuropathy in patients with breast cancer: a systematic review.
Synthesis in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Body composition changes in women with early breast cancer after adjuvant treatment: a systematic review.Acta oncologica (Stockholm, Sweden) · 2025Pooled it
- Limb cold therapy for preventing paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled study.World journal of surgical oncology · 2026Trial
- Trial
- Effects of an exercise program on chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer individuals receiving taxanes: a randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Precision acupuncture for chemotherapy-induced peripheral neuropathy: multitarget mechanisms and integrated clinical translation framework.Frontiers in neurology · 2026Review
- Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.Nature reviews. Cancer · 2025Review
- Risk factors and interrelationships of taxane-related peripheral neuropathy: a Bayesian network analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Effectiveness of Statins for Oxaliplatin-Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study.Clinical and translational science · 2025Observational
- Gender and age effects on the incidence and severity of chemotherapy-induced neuropathic pain: a propensity score matching analysis.BMC cancer · 2025Article
- Article
- Real-world 12-month outcomes of repeated high-concentration capsaicin patch in chemotherapy-induced peripheral neuropathy: results from the CASPAR study.Frontiers in oncology · 2025Article
- Modified Wen Luo Tong Alleviated Chemotherapy-Induced Peripheral Neuropathy via Regulating the CX3CL1/CX3CR1 Axis Through Inhibiting NF-κB and STAT3 Pathways.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeChemotherapy-induced peripheral neuropathy (CIPN) is a common dose limiting adverse effect that may be transient or become persistent after the treatment ended. The taxane paclitaxel induces CIPN in 57-83% of patients treated. The neuropathy may debut or progress after the end of treatment (EOT), known as coasting, but little is known about the incidence of this phenomenon. The aim of this review is to examine the incidence and severity of coasting in CIPN in patients with breast cancer. Patient/material and methods: MEDLINE, Embase, clinicaltrials.gov, and medrivx.org were searched using terms related to taxanes, adverse effects, and breast cancer. Studies had to have a follow-up time of at least 3 months after EOT and patients had to have received taxanes in monotherapy. Additionally, studies had to be longitudinal and describe the neuropathy assessment method and timing.
resultsA total of 17 studies met the eligibility criteria, with 4,265 participants summarized. Of these, one study reported coasting events in 14.3% (n = 4) of patients. Eight studies reported no coasting events and eight were unclear.
interpretationFew studies reported on coasting in CIPN. There may be several reasons for this, including the timing and choice of assessment methods, confounding factors, and the possible rarity of the phenomenon. More information is needed about coasting in CIPN to better characterize the neuropathies, guide patient and doctor decisions, and aid in the development of interventions toward CIPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.